Chairman of the Egyptian Drug Authority (EDA), Ali el-Ghamrawy, received on Tuesday Dr Khaled Sari, General Manager of Takeda Pharmaceutical Company Limited, along with his accompanying delegation to discuss avenues for expanding strategic collaboration.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader, headquartered in Japan.
The meeting focused on enhancing joint initiatives and aligning future projects with Egypt’s national vision to strengthen the healthcare sector and advance the domestic pharmaceutical industry. Key discussions included initiatives and policies to improve access to medicines for Egyptian patients and facilitate the availability of innovative therapies in priority treatment areas.
Takeda representatives provided updates on their clinical trials and research activities in Egypt, underscoring the importance of continued coordination with the EDA to support scientific research and innovation.
The delegation also reviewed the EDA’s intellectual property policies, designed to create an investment-friendly environment that meets international standards.
El-Ghamrawy reaffirmed the authority’s commitment to advancing clinical research and positioning Egypt as a regional hub for pharmaceutical research and development, emphasising the role of strategic partnerships in fostering innovation and improving patient care.
